Active Infection & Immunity Cancer

Clonal and functional T cell determinants of protection and pathogenesis in tuberculosis.

In plain English

AI plain-English summary

Tuberculosis kills 1.5 million people each year, and T cells—the immune system's frontline defenders—are failing some people without clear reason. The problem is especially stark for people living with HIV, who face persistently high TB risk even after antiretroviral therapy restores their T cell counts. This project will compare the T cells that react to *Mycobacterium tuberculosis* in HIV-positive and HIV-negative individuals, testing whether the dominant T cells in treated HIV patients are less diverse, target different bacterial proteins, or function differently. The researchers will then link those T cell traits to how well immune cells called macrophages can control TB growth in the lab, and test whether the same traits predict disease risk in large population cohorts. If successful, the work could sharpen vaccine design by revealing which T cell responses actually protect, enable doctors to identify who most needs preventative antibiotics, and open routes to therapies that correct faulty T cell function. This is fundamental immunology with a direct line to clinical tools—no daily-life connection needed, but a clear path to fewer deaths.

View original technical description
Tuberculosis (TB), resulting from infection with Mycobacterium tuberculosis (Mtb), kills 1.5 million people per year. The immune system prevents disease in most people who become infected, but the mechanisms of immune protection and pathogenesis remain critical knowledge gaps. T cells are necessary for protective immunity, but we do not know the precise T cell traits that influence different outcomes of infection. People living with HIV (PLWH) have persistently increased TB disease-risk and exhibit persistent abnormalities of T cell clonal and functional repertoires, despite long-term antiretroviral therapy (ART). We will use cutting-edge methodology to comprehensively detail perturbation of in vivo human Mtb-reactive T cell responses in this group, independent of total T cell counts. We will test the hypothesis that dominant Mtb-reactive T cells in ART-treated PLWH have restricted clonality, target different antigens and exhibit different functionality, compared to those of HIV-negative individuals. We will identify which of these T cell traits impact on macrophage control of Mtb-growth, and predict disease-risk in multiple independent cohorts sampled from the general population. We expect our findings to drive innovations in vaccine development and evaluation, personalised risk-stratification to enable precision targeting of preventative antimicrobial treatment, and development of immunomodulatory therapies for disease. "

View the original record at the funder ↗

Researchers

Alasdair Leslie (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Investigating T cell compromise of macrophage defence in tuberculosis
Defining protective immunity to human tuberculosis.
Investigating the functional role of CD1 expression and defining protective and pathogenic CD1c-immunity in tuberculosis.
Investigating local determinants of outcome in human tuberculosis
Trained immunity in the pathogenesis of tuberculosis

Original classification

Discovery Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.